Detalles de la búsqueda
1.
Stabilization of a soluble, native-like trimeric form of an efficiently cleaved Indian HIV-1 clade C envelope glycoprotein.
J Biol Chem
; 292(20): 8236-8243, 2017 05 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-28283570
2.
Cell surface ectodomain integrity of a subset of functional HIV-1 envelopes is dependent on a conserved hydrophilic domain containing region in their C-terminal tail.
Retrovirology
; 15(1): 50, 2018 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30029604
3.
Correction: Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.
PLoS Pathog
; 12(5): e1005674, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27219002
4.
Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.
PLoS Pathog
; 12(4): e1005537, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27064278
5.
Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
J Virol
; 90(7): 3446-57, 2016 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-26763999
6.
Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.
Retrovirology
; 13(1): 81, 2016 Nov 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-27871328
7.
Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.
Retrovirology
; 13(1): 41, 2016 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27307004
8.
Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates.
J Virol
; 87(24): 13239-51, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24067980
9.
Anti-HIV B Cell lines as candidate vaccine biosensors.
J Immunol
; 189(10): 4816-24, 2012 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23066156
10.
HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
J Virol
; 86(20): 11231-41, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22875963
11.
Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site.
PLoS Pathog
; 5(5): e1000445, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19478876
12.
Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
Vaccine
; 36(12): 1627-1636, 2018 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29429810
13.
Ligand accessibility to the HIV-1 Env co-receptor binding site can occur prior to CD4 engagement and is independent of viral tier category.
Virology
; 519: 99-105, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29684630
14.
Identification and characterization of a naturally occurring, efficiently cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with properties comparable to membrane-bound BG505.
Virology
; 510: 22-28, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28689085
15.
An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies.
PLoS One
; 10(3): e0122443, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25822521
16.
Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner.
Virology
; 462-463: 266-72, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24999839
17.
HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
AIDS Res Hum Retroviruses
; 27(8): 877-87, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21158699
18.
Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2.
J Virol
; 81(3): 1444-50, 2007 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17093191
19.
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
J Infect Dis
; 194(12): 1650-60, 2006 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17109336
20.
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.
Clin Vaccine Immunol
; 13(11): 1267-77, 2006 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16988008